Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: HAIC+Serplulimab （HLX10）+ Bevacizumab Biosimilar（HLX04） Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Drug: AK104; Drug: Lenvatinib; Procedure: TACE; Other: Placebo for AK104; Other: Placebo for Lenvatinib Sponsors: Akeso Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular Carcinoma
Conditions: Lymphopenia Sponsors: Chang Gung Memorial Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
Conditions: Hepatocellular Carcinoma, Non-cirrhotic Liver Interventions: Other Sponsors: Xiao Xu Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: Targeted drugs; Drug: PD-1 monoclonal antibody Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: PD-1 monoclonal antibody; Drug: targeted drugs Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Shanghai Zhongshan Hospital; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Econd-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Hui-Chuan Sun; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
Conditions: Hepatocellular Carcinoma Interventions: Drug: TKI+Cardunilimab Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: camrelizumab Sponsors: Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: HAIC+STRIDE+Len Sponsors: Sulai Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: Adebrelimab plus Apatinib; Drug: Adebrelimab plus Bevacizumab; Drug: Camrelizumab plus Apatinib Sponsors: Peking University Cancer Hospital& Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
EchoTip AcuCore Post-Market Clinical Study
Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis Interventions: Device: EchoTip AcuCore Sponsors: Cook Research Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
